Long-Term Outcomes of the Offspring of Mothers with Autoimmune Rheumatic Diseases

The long-term outcomes of children born to mothers with autoimmune rheumatic diseases (AIRDs) have been a topic of ongoing debate. Concerns primarily arise from the potential impact of maternal therapies used during pregnancy, the transplacental passage of autoantibodies, and the influence of the autoimmune condition itself. Most immunosuppressive and disease-modifying drugs commonly used during pregnancy are now considered relatively safe for both mother and fetus, provided they are administered under close medical supervision. Although certain maternal autoantibodies can cross the placenta, the incidence of related neonatal complications remains low. Furthermore, the development of AIRDs in the offspring is rare, even though long-term follow-up studies are still limited. Some earlier research raised concerns about an increased risk of neurodevelopmental disorders in children born to mothers with autoimmune conditions. However, more recent and comprehensive investigations have shown that such occurrences are infrequent. Overall, maternal autoimmunity and its treatment do not appear to have a significant negative effect on the long-term health and development of the child.